Home  |  Contact

UniProtKB/Swiss-Prot Q71SY5: Variant p.Ala335Val

Mediator of RNA polymerase II transcription subunit 25
Gene: MED25
Variant information

Variant position:  335
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Alanine (A) to Valine (V) at position 335 (A335V, p.Ala335Val).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from small size and hydrophobic (A) to medium size and hydrophobic (V)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CMT2B2.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.

Sequence information

Variant position:  335
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  747
The length of the canonical sequence.

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         GVGPPFS----------------------------------------------------------------------QAPAPQLPP---GPP----------------GAPKPP----PASQPSLVSTVAPGSG

Mouse                         GVGPPFS----------------------------------

Bovine                        GVGPPYS----------------------------------

Xenopus laevis                AVGTPFN----------------------------------

Xenopus tropicalis            AVGTPFN----------------------------------

Zebrafish                     PVLPPGG----------------------------------


Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

Chain 1 – 747 Mediator of RNA polymerase II transcription subunit 25
Compositional bias 200 – 381 Pro-rich

Literature citations

Identification of the variant Ala335Val of MED25 as responsible for CMT2B2: molecular data, functional studies of the SH3 recognition motif and correlation between wild-type MED25 and PMP22 RNA levels in CMT1A animal models.
Leal A.; Huehne K.; Bauer F.; Sticht H.; Berger P.; Suter U.; Morera B.; Del Valle G.; Lupski J.R.; Ekici A.; Pasutto F.; Endele S.; Barrantes R.; Berghoff C.; Berghoff M.; Neundoerfer B.; Heuss D.; Dorn T.; Young P.; Santolin L.; Uhlmann T.; Meisterernst M.; Sereda M.W.; Sereda M.; Stassart R.M.; Zu Horste G.M.; Nave K.A.; Reis A.; Rautenstrauss B.;
Neurogenetics 10:275-287(2009)
Cited for: VARIANT CMT2B2 VAL-335;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.